Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 0.60 |
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | SRC | P12931 | 6/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.60 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.60 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.60 |
| ▸ | WEE1 | P30291 | 5/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | STK25 | O00506 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382360 | 0.84 | FGFR1 (0.61) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL5761783 | 0.82 | FGFR1 (0.70) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL23088812 | 0.80 | FGFR1 (0.60) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL5761991 | 0.78 | FGFR1 (0.70) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL30618265 | 0.78 | FGFR1 (0.70) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL25399083 | 0.78 | FGFR1 (0.77) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL5763098 | 0.77 | FGFR1 (0.75) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL5763230 | 0.76 | FGFR1 (0.73) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL4839269 | 0.76 | FGFR1 (1.00) | FGFR1EGFRSRCFGFR2FGFR4 | |
| SCHEMBL3762584 | 0.75 | FGFR1 (0.69) | FGFR1EGFRSRCFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258623-B2 | Compositions and methods for reduction of amyloid-beta load | MODGENE, LLC (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170360787-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | MODGENE, LLC | 2017-12-21 | — | — | US | disclosed |
| US-9707231-B2 | Compositions and methods for reduction of amyloid-beta load | MODGENE, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160287587-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | MODGENE, LLC | 2016-10-06 | — | — | US | disclosed |
| EP-2776035-B1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | MODGENE LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2365804-B1 | REDUCTION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | MODGENE LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140323496-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | MODGENE, LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20100120787-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | MODGENE, LLC (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360787-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | BACE1, APP, BACE2 | FGFR1 3612/4885EGFR 4103/4885SRC 2106/4885 |
| US-10258623-B2 | Compositions and methods for reduction of amyloid-beta load | BACE1, APP, BACE2 | FGFR1 3356/4885EGFR 3738/4885SRC 1849/4885 |
| US-20100120787-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | BACE1, APP, BACE2 | FGFR1 2779/4885EGFR 3222/4885SRC 1788/4885 |
| US-20140323496-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | BACE1, APP, BACE2 | FGFR1 3356/4885EGFR 3738/4885SRC 1849/4885 |
| US-20160287587-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | BACE1, APP, BACE2 | FGFR1 2779/4885EGFR 3222/4885SRC 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.